COMMUNIQUÉS West-GlobeNewswire

Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
17/12/2025
COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the [...]
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
17/12/2025
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA [...]
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
17/12/2025
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
Festive drinking and hormones: Clue shares science-backed guidance for Christmas
17/12/2025
LONDON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- With office parties, cocktails with friends and end-of-year celebrations in full swing, many of us brace for hangovers without realising that festive drinking can have a real [...]
Communiqué de presse : L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine
17/12/2025
L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine Une désignation de médicament orphelin supplémentaire renforce l’engagement [...]
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
17/12/2025
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseases [...]
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas
17/12/2025
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas Premières implantations Genio réalisées avec succès dans les hôpitaux OLVG West et Zuyderland Mont-Saint-Guibert, Belgique – 17 [...]
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
17/12/2025
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7: [...]
Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire »
17/12/2025
Mise en ligne du document «Q4 2025 Aide mémoire » Paris, France, le 17 décembre 2025 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q4 2025 Aide [...]
Press release: Availability of the Q4 2025 Aide memoire
17/12/2025
Availability of the Q4 2025 Aide memoire Paris, France – December 17, 2025 . Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full [...]
Vireo Growth Inc. Enters into Definitive Agreement to Acquire Certain Assets of PharmaCann Inc.
17/12/2025
Acquired assets further optimize Vireo’s operating footprint in Colorado with addition of 17 dispensaries Transaction expands Vireo’s leadership position in the Colorado retail market with 41 total dispensaries Parties [...]
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference
16/12/2025
CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan [...]
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare Conference
16/12/2025
WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will [...]
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
16/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
16/12/2025
– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and [...]
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide
16/12/2025
Châtillon, France, le 16 décembre 2025 DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN ® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’ [...]
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
16/12/2025
Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: [...]

Pages